Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 17.12 -6.50% -1.19
DRNA closed down 6.5 percent on Friday, March 27, 2020, on 1.21 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical DRNA trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.50%
200 DMA Support Bullish -6.50%
NR7 Range Contraction -6.50%
Wide Bands Range Expansion -6.50%
Up 3 Days in a Row Strength -6.50%
Up 4 Days in a Row Strength -6.50%
1,2,3 Retracement Bearish Bearish Swing Setup -4.94%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Medicine Biopharmaceutical Cancer Diseases Disease Cancers Enzymes Paroxysmal Nocturnal Hemoglobinuria Liver Liver Diseases Cardiomyopathy Carcinogenesis Familial Amyloid Polyneuropathy Hemophilia A Ras Subfamily C Met Drug Delivery Technologies Hyperoxaluria Primary Hyperoxaluria Treatment Of Various Cancers

Is DRNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.68
52 Week Low 10.7
Average Volume 695,687
200-Day Moving Average 17.79
50-Day Moving Average 19.09
20-Day Moving Average 17.24
10-Day Moving Average 15.90
Average True Range 1.70
ADX 27.86
+DI 18.98
-DI 24.35
Chandelier Exit (Long, 3 ATRs ) 16.24
Chandelier Exit (Short, 3 ATRs ) 16.85
Upper Bollinger Band 21.63
Lower Bollinger Band 12.85
Percent B (%b) 0.49
BandWidth 50.93
MACD Line -0.73
MACD Signal Line -1.06
MACD Histogram 0.3295
Fundamentals Value
Market Cap 356.86 Million
Num Shares 20.8 Million
EPS -3.20
Price-to-Earnings (P/E) Ratio -5.35
Price-to-Sales 155.10
Price-to-Book 7.93
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.23
Resistance 3 (R3) 20.40 19.53 19.71
Resistance 2 (R2) 19.53 18.74 19.45 19.53
Resistance 1 (R1) 18.33 18.25 17.90 18.16 19.36
Pivot Point 17.46 17.46 17.25 17.38 17.46
Support 1 (S1) 16.26 16.67 15.83 16.09 14.88
Support 2 (S2) 15.39 16.18 15.31 14.71
Support 3 (S3) 14.19 15.39 14.53
Support 4 (S4) 14.02